The STAT3 inhibitor (S3I-201) ameliorates RAS activation and reduces the local production of VEGF in podocytes and renal tubule epithelium, which are induced by elevated ACE levels in diabetes (Zheng et al., 2019). The gene discussed is STAT3; the disease is diabetes mellitus.